当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

Abstract：

:The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to assess the drug sensitivity of cancer cells. For this purpose we submitted chemosensitive and chemoresistant cell lines to different anticancer drugs and monitored the cell growth and the drug-induced morphonuclear effects by means of digital cell-image analysis of Feulgen-stained nuclei. The results showed that drug-induced effects at the morphonuclear level correlated statistically with the effects produced at the cell proliferation level. For example, the mean nuclear size value increased as a function of the drugs' efficiency recorded at the cell proliferation level. In the same way, the frequency of large dense chromatin clumps also increased in accordance with the drugs' efficiency. The present work thus demonstrates that digital cell-image analysis can be applied to monitor the efficiency of chemotherapeutic treatment carried out on cell lines in vitro. The present methodology could possibly be used on solid tumors, from which biological material can be obtained serially by means of fine-needle aspiration. As evidence of this, the present methodology can also be applied to hematological cancers.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Pauwels O,Kiss R

doi

10.1007/BF00685647

subject

Has Abstract

pub_date

1995-01-01 00:00:00

pages

179-86

issue

1-2

eissn

0344-5704

issn

1432-0843

journal_volume

37

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.

    abstract：BACKGROUND:Ovarian cancer is one of the most frequently fatal gynecological cancers because most cases are diagnosed at an advanced stage. Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumor progression. Little is known about the effect of various treatment regimens...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-004-0993-9

    authors： Dutta T,Sharma H,Kumar L,Dinda AK,Kumar S,Bhatla N,Singh N

    更新日期：2005-10-01 00:00:00

  • Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.

    abstract：PURPOSE:To evaluate the effect of renal impairment on eribulin mesylate pharmacokinetics following a single dose in adults with advanced solid tumors. METHODS:Patients were grouped by renal function: moderate impairment (creatinine clearance [CrCl] 30-50 mL/min), severe impairment (CrCl 15-29 mL/min), or normal (CrCl ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s00280-015-2878-5

    authors： Tan AR,Sarantopoulos J,Lee L,Reyderman L,He Y,Olivo M,Goel S

    更新日期：2015-11-01 00:00:00

  • Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy.

    abstract：:Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. Our group has shown that MB was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). However, there are no studies comparing the cytotoxicity of this molecule for ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-1014-3

    authors： Kirszberg C,Rumjanek VM,Capella MA

    更新日期：2005-12-01 00:00:00

  • Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.

    abstract：PURPOSE:Carboplatin is frequently dosed to achieve a desired area under the plasma concentration-time curve (AUC) by using the Calvert or Chatelut equations to estimate carboplatin clearance. Accurate determination of glomerular filtration rate (GFR) is necessary to correctly calculate carboplatin clearance using the C...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800000260

    authors： Donahue A,McCune JS,Faucette S,Gillenwater HH,Kowalski RJ,Socinski MA,Lindley C

    更新日期：2001-05-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.

    abstract：:Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essential for this activity. We performed a pharmacokinetics study as part ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050479

    authors： van Warmerdam LJ,Creemers GJ,Rodenhuis S,Rosing H,de Boer-Dennert M,Schellens JH,ten Bokkel Huinink WW,Davies BE,Maes RA,Verweij J,Beijnen JH

    更新日期：1996-01-01 00:00:00

  • Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.

    abstract：:Mitoxantrone, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride, a new antitumor agent was evaluated in nine cancer patients as part of a phase I trial. In general, the drug was well tolerated. Leukopenia was the dose-limiting toxic effect. Mild to moderate leukopenia...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00578556

    authors： Alberts DS,Griffith KS,Goodman GE,Herman TS,Murray E

    更新日期：1980-01-01 00:00:00

  • Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.

    abstract：:The pharmacokinetic parameters of the alkylating agent melphalan were determined in 15 children and 11 adults with advanced malignant solid tumors. High IV bolus doses of 140 mg/m2 were given under standard hyperhydration conditions and followed by autologous bone marrow grafting. In all cases the time-concentration c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00293997

    authors： Ardiet C,Tranchand B,Biron P,Rebattu P,Philip T

    更新日期：1986-01-01 00:00:00

  • A phase I trial of flavopiridol in relapsed multiple myeloma.

    abstract：PURPOSE:Flavopiridol is primarily a cyclin-dependent kinase-9 inhibitor, and we performed a dose escalation trial to determine the maximum tolerated dose and safety and generate a pharmacokinetic (PK) profile. METHODS:Patients with a diagnosis of relapsed myeloma after at least two prior treatments were included. Flav...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-013-2347-y

    authors： Hofmeister CC,Poi M,Bowers MA,Zhao W,Phelps MA,Benson DM,Kraut EH,Farag S,Efebera YA,Sexton J,Lin TS,Grever M,Byrd JC

    更新日期：2014-02-01 00:00:00

  • Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).

    abstract：:We studied bioavailability, treatment schedule dependence, and therapeutic efficacy of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine), against murine tumors and human tumor xenografts. The rate of its intestinal absorption was about 50%, and it was immediately metabolized to its parent comp...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685528

    authors： Narita T,Koide Y,Yaguchi S,Kimura S,Izumisawa Y,Takase M,Inaba M,Tsukagoshi S

    更新日期：1991-01-01 00:00:00

  • Dosing algorithm revisit for busulfan following IV infusion.

    abstract：PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-014-2660-0

    authors： Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

    更新日期：2015-03-01 00:00:00

  • Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.

    abstract：:We previously reported (UroOncology 1:165, 2001) cross-resistance and collateral-sensitivity to 2-chlorodeoxyadenosine (CldAdo) and fludarabine (FaraA), respectively, in a human renal cell carcinoma selected for resistance to 2'-deoxytubercidin (Caki-dTub). Insofar that these drugs generally demonstrate cross resistan...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0351-1

    authors： Pan BF,Nelson JA

    更新日期：2007-04-01 00:00:00

  • Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

    abstract：PURPOSE:This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling. METHODS:Patients with advanced cancers received salirasib twice daily for 21 days every 4 weeks. Doses were escalated from 100 to 200, 400, 600, and 800 mg. RESULTS:The ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-1027-4

    authors： Tsimberidou AM,Rudek MA,Hong D,Ng CS,Blair J,Goldsweig H,Kurzrock R

    更新日期：2010-01-01 00:00:00

  • In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays.

    abstract：:6-[Bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose (C-6) is a new glucose-containing nitrogen mustard that has significant activity for murine P388 leukemia with relative sparing of bone marrow in mice. The in vitro myelotoxicity of C-6 compared with that of melphalan, a clinically active, myelosuppressive nitrogen musta...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00256165

    authors： Lazarus P,Dufour M,Isabel G,Panasci LC

    更新日期：1986-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

    abstract：PURPOSE:Thalidomide, originally developed as a sedative, was subsequently identified to have antiangiogenic properties. Lenalidomide is an antiangiogenic and immunomodulatory agent that has been utilized in the treatment of patients with brain tumors. We studied the pharmacokinetics and cerebrospinal fluid (CSF) penetr...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1781-y

    authors： Muscal JA,Sun Y,Nuchtern JG,Dauser RC,McGuffey LH,Gibson BW,Berg SL

    更新日期：2012-04-01 00:00:00

  • Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.

    abstract：:Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mea...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00434388

    authors： Howell SB,Mansfield SJ,Taetle R

    更新日期：1981-01-01 00:00:00

  • A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.

    abstract：PURPOSE:The objectives of these analyses were to (1) develop a semimechanistic-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model to describe neutropenic response to pemetrexed and to (2) identify influential covariates with respect to pharmacodynamic response. PATIENTS AND METHODS:Data from 279 pati...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-005-0077-5

    authors： Latz JE,Karlsson MO,Rusthoven JJ,Ghosh A,Johnson RD

    更新日期：2006-04-01 00:00:00

  • Targeting the neddylation pathway in cells as a potential therapeutic approach for diseases.

    abstract：:The ubiquitin-proteasome system (UPS) is an important system that regulates the balance of intracellular proteins, and it is involved in the regulation of multiple vital biological processes. The approval of bortezomib for relapsed and refractory multiple myeloma has proven that agents targeting the UPS have the poten...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-018-3541-8

    authors： Ying J,Zhang M,Qiu X,Lu Y

    更新日期：2018-05-01 00:00:00

  • Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.

    abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2862-0

    authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

    更新日期：2015-11-01 00:00:00

  • A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.

    abstract：:Despite its rapid enzymatic inactivation and therefore limited activity in vivo, Gemcitabine is the standard drug for pancreatic cancer treatment. To protect the drug, and achieve passive tumor targeting, we developed a liposomal formulation of Gemcitabine, GemLip (Ø: 36 nm: 47% entrapment). Its anti-tumoral activity ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0482-z

    authors： Bornmann C,Graeser R,Esser N,Ziroli V,Jantscheff P,Keck T,Unger C,Hopt UT,Adam U,Schaechtele C,Massing U,von Dobschuetz E

    更新日期：2008-03-01 00:00:00

  • Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.

    abstract：PURPOSE:To compare the response rates, toxicities and survival durations of elderly patients (70 years of age or more) with those of younger patients (less than 70 years of age) with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. PATIENTS AND METHODS:We analyzed retrospectively the data ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s002800050689

    authors： Kubota K,Furuse K,Kawahara M,Kodama N,Ogawara M,Takada M,Masuda N,Negoro S,Matsui K,Takifuji N,Kudoh S,Kusunoki Y,Fukuoka M

    更新日期：1997-01-01 00:00:00

  • In vitro succinate dehydrogenase chemosensitivity of gastric carcinoma--relationship to DNA content.

    abstract：:Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was micros...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00686250

    authors： Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

    更新日期：1992-01-01 00:00:00

  • Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

    abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0554-0

    authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

    更新日期：2008-05-01 00:00:00

  • 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.

    abstract：PURPOSE:2-Methoxyestradiol (2-ME) is a physiological metabolite of estrogen, which can inhibit growth of many types of tumor cells, including hepatocellular carcinoma, both in vitro and in vivo. The exact mechanisms of its action are still unclear. We have studied the mechanisms of growth inhibition of several of human...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0670-x

    authors： Kar S,Wang M,Carr BI

    更新日期：2008-10-01 00:00:00

  • Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.

    abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s00280-002-0443-5

    authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

    更新日期：2002-07-01 00:00:00

  • Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.

    abstract：PURPOSE:To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS:Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three pat...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2781-0

    authors： Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D,Gentet JC,Bracard S,André N

    更新日期：2015-08-01 00:00:00

  • Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

    abstract：:There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s00280-014-2536-3

    authors： Chiu CH,Chou TY,Chiang CL,Tsai CM

    更新日期：2014-10-01 00:00:00

  • Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

    abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0370-y

    authors： Katori H,Tsukuda M,Watai K

    更新日期：2007-08-01 00:00:00

  • Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy.

    abstract：PURPOSE:Previous studies have shown that angiotensin peptides stimulate the proliferation of hematopoietic progenitors in vitro, promote survival after exposure to lethal irradiation as well as accelerate the recovery of white blood cells (WBC), i.e., lymphocytes, monocytes and neutrophils, and platelets. These changes...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-002-0509-4

    authors： Rodgers K,Xiong S,DiZerega GS

    更新日期：2003-02-01 00:00:00

  • Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.

    abstract：:To predict the clinical effect on leukemic disease of a combination regimen developed to circumvent multidrug resistance (MDR), we tested various antitumor agents in the presence and absence of AHC-52, a sensitizing agent for multidrug-resistant cells, in the i.v.-i.v. model of murine leukemia. In this model system, s...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689959

    authors： Shinoda H,Ebisu H,Mitsuhashi J,Inaba M,Tsuruo T

    更新日期：1992-01-01 00:00:00

  • Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

    abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00689280

    authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

    更新日期：1990-01-01 00:00:00